Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biopharmaceutical company Anesiva and Sagent Pharmaceuticals have entered into an agreement under which Sagent will co-promote and manage US distribution for Anesiva's Zingo powder intradermal needle-free injection for pain reduction.
Subscribe to our email newsletter
Zingo provides fast-acting topical, local analgesia, to reduce the pain associated with venous access procedures, such as IV insertions or blood draws, in children three to 18 years of age.
Under the agreement, which will last three years, Sagent will join with Anesiva to co-promote Zingo within hospitals as well as facilitating contract negotiations with hospitals and group purchasing organizations. Sagent’s team will focus their selling efforts toward hospital pharmacists, with Anesiva promoting primarily to physicians and nurses.
Sagent will manage Zingo warehousing and distribution services. The terms of the agreement provide for Sagent to earn a royalty based on Anesiva’s net sales of Zingo, and for Anesiva to reimburse Sagent for certain direct expenses. Anesiva may designate additional marketing partners to address non-hospital affiliated markets.
John McLaughlin, CEO of Anesiva, said: “Together with Anesiva’s experienced marketing organization and planned sales force of 15 representatives, we will have complementary roles and provide synergistic selling efforts to launch Zingo successfully in US hospitals. Anesiva will also leverage Sagent’s established infrastructure for warehousing and distribution services.”